Viking Therapeutics, Inc. (VKTX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 3.53B USD. 52-week range 25.77 to 43.15 USD. Data as of 2026-10-09.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal ...